Company profile: Theolytics
1.1 - Company Overview
Company description
- Provider of next-generation viral therapies, leveraging phenotypic screening platforms to discover targeted oncolytic adenoviral candidates suitable for intravenous delivery and optimized for specific patient populations. Offerings include THEO-260 for platinum-resistant ovarian cancer, THEO-310 for multiple myeloma, proprietary adenovirus libraries for oncology, gene therapy and infectious diseases, and bioselection/screening systems.
Products and services
- Discovery Platforms: Phenotypic-screening-driven systems that discover and develop efficacious, targeted adenoviral candidates suitable for intravenous delivery and optimized for defined patient populations
- THEO-260: Custom-engineered, next-generation oncolytic adenovirus for platinum-resistant ovarian cancer, killing cancer cells and cancer-associated fibroblasts while stimulating the immune system
- THEO-310: Ex vivo-validated oncolytic virus targeting the bone marrow tumor microenvironment in multiple myeloma, showing efficacy in ex vivo bone marrow aspirates
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theolytics
Tilos Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics targeting key immunological pathways, with a focus on regulatory T cells and effector cell regulation; developing anti-LAP antibodies specific to the Latency Associated Peptide of TGF beta for cancer treatment. Founded in 2016 and based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilos Therapeutics company profile →
Suros Surgical
HQ: United States
Website
- Description: Provider of award-winning, Indiana-based medical devices enabling minimally invasive tissue excision and biopsy across multiple surgical specialties, built on patented surgical platform technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suros Surgical company profile →
Acerta Pharma
HQ: United States
Website
- Description: Provider of oncology and autoimmune drug discovery and development, including CALQUENCE (acalabrutinib) for CLL; collaborative small-molecule discovery for hematologic malignancies; innovative clinical studies; resistance biology research using multi-omic profiling; R&D on target identification and optimization; and partnering and in-licensing opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acerta Pharma company profile →
Kiadis Pharma
HQ: The Netherlands
Website
- Description: Provider of novel biopharmaceutical treatment options focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients, with three products in clinical development addressing high-unmet medical needs of terminally ill cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kiadis Pharma company profile →
Kiyatec
HQ: United States
Website
- Description: Provider of ex vivo 3D cell culture technology that uses a patient's own living tumor cells to create functional microtumor models for testing cancer therapies and predicting response. Offers 3D Predict Glioma and 3D Predict Oncology, patient-specific microtumor creation (up to 1,000) for drug testing, and a HIPAA-compliant portal delivering patient-specific reports within 7-10 days to aid treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kiyatec company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theolytics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theolytics
2.2 - Growth funds investing in similar companies to Theolytics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theolytics
4.2 - Public trading comparable groups for Theolytics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →